Surgery induced immunosuppression

Surgeon

Volumn 9, Issue 1, 2011, Pages 38-43

  Hogan, Brian V ^a   Peter, Mark B ^a   Shenoy, Hrishikesh G ^a   Horgan, Kieran ^a   Hughes, Thomas A ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Immunity; Infection; Metastases; Post operative; Surgery

Indexed keywords

HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; POSTOPERATIVE PERIOD; REVIEW; SURGERY;

HUMANS; IMMUNE TOLERANCE; POSTOPERATIVE PERIOD; STRESS, PHYSIOLOGICAL; SURGICAL PROCEDURES, OPERATIVE;

EID: 78650678978     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2010.07.011     Document Type: Review

References (96)

1. Redmond H.P., Watson W., Hougton T., Condron C., Watson R.G., Hayes D.B. Immune function in patients undergoing open vs laparoscopic cholecystectomy. Arch Surg 1994, 129(12):1240-1246.
2. Lennard T.W., Shenton B.K., Borzotta A., Donnelly P.K., White M., Gerrie L.M., et al. The influence of surgical operations on components of the human immune system. Br J Surg 1985, 72(10):771-776.
3. Ogawa K., Hirai M., Katsube T., Murayama M., Hamaguchi K., Shimakawa T., et al. Suppression of cellular immunity by surgical stress. Surgery 2000, 127(3):329-336.
4. Vallina V.L., Velasco J.M. The influence of laparoscopy on lymphocyte subpopulations in the surgical patient. Surg Endosc 1996, 10(5):481-484.
5. Cristaldi M., Rovati M., Elli M., Gerlinzani S., Lesma A., Balzarotti L., et al. Lymphocytic subpopulation changes after open and laparoscopic cholecystectomy: a prospective and comparative study on 38 patients. Surg Laparosc Endosc 1997, 7(3):255-261.
6. Leaver H.A., Craig S.R., Yap P.L., Walker W.S. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest 2000, 30(3):230-238.
7. Salo M., Eskola J., Nikoskelainen J. T and B lymphocyte function in anaesthetists. Acta Anaesthesiol Scand 1984, 28(3):292-295.
8. Ferrero E., Ferrero M.E., Marni A., Zocchi M.R., Stella L., Rugarli C., et al. In vitro effects of halothane on lymphocytes. Eur J Anaesthesiol 1986, 3(4):321-330.
9. Toft P., Lillevang S.T., Tønnesen E., Svendsen P., Höhndorf K. Redistribution of lymphocytes following E. coli sepsis. Scand J Immunol 1993, 38(6):541-545.
10. Shafir M., Bekesi J.G., Papatestas A., Slater G., Aufses A.H. Preoperative and postoperative immunological evaluation of patients with colorectal cancer. Cancer 1980, 46(4):700-705.
11. Brune I.B., Wilke W., Hensler T., Holzmann B., Siewert J.R. Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999, 177(1):55-60.
12. Decker D., Lindemann C., Springer W., Low A., Hirner A., von Ruecker A. Endoscopic vs conventional hernia repair from an immunologic point of view. Surg Endosc 1999, 13(4):335-339.
13. Ishikawa M., Nishioka M., Hanaki N., Miyauchi T., Kashiwagi Y., Ioki H., et al. Perioperative immune responses in cancer patients undergoing digestive surgeries. World J Surg Oncol 2009, 7:7.
14. Wichmann M.W., Hüttl T.P., Winter H., Spelsberg F., Angele M.K., Heiss M.M., et al. Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg 2005, 140(7):692-697.
15. Tonnesen E. Immunological aspects of anaesthesia and surgery-with special reference to NK cells. Dan Med Bull 1989, 36(3):263-281.
16. Lukomska B., Olszewski W.L., Engeset A., Kolstad P. The effect of surgery and chemotherapy on blood NK cell activity in patients with ovarian cancer. Cancer 1983, 51(3):465-469.
17. Koltun W.A., McKenna K.J., Rung G. Awake epidural anesthesia is associated with improved natural killer cell cytotoxicity and a reduced stress response. Am J Surg 1996, 171(1):68-72. discussion 72-3.
18. Slade M.S., Simmons L., Yunis E., Greenberg L.J. Immunodepression after major surgery in normal patients. Surgery 1975, 78(3):363-372.
19. van Dijk W.C., Verbrugh H.A., van Rijswijk R.E., Vos A., Verhoef J. Neutrophil function, serum opsonic activity, and delayed hypersensitivity in surgical patients. Surgery 1982, 92(1):21-29.
20. 2+ mobilization in human neutrophils by halothane, enflurane, and isoflurane. Anesthesiology 1986, 64(1):4-12.
21. Fröhlich D., Rothe G., Schwall B., Schmid P., Schmitz G., Taeger K., et al. Effects of volatile anaesthetics on human neutrophil oxidative response to the bacterial peptide FMLP. Br J Anaesth 1997, 78(6):718-723.
22. Welch W.D. Halothane reversibly inhibits human neutrophil bacterial killing. Anesthesiology 1981, 55(6):650-654.
23. Kawasaki T., Ogata M., Kawasaki C., Okamoto K., Sata T. Effects of epidural anaesthesia on surgical stress-induced immunosuppression during upper abdominal surgery. Br J Anaesth 2007, 98(2):196-203.
24. Moudgil G.C., Pandya A.R., Ludlow D.J. Influence of anaesthesia and surgery on neutrophil chemotaxis. Can Anaesth Soc J 1981, 28(3):232-238.
25. Carey P.D., Wakefield C.H., Thayeb A., Monson J.R., Darzi A., Guillou P.J. Effects of minimally invasive surgery on hypochlorous acid production by neutrophils. Br J Surg 1994, 81(4):557-560.
26. Wu G.J., Tai Y.T., Chen T.L., Lin L.L., Ueng Y.F., Chen R.M. Propofol specifically inhibits mitochondrial membrane potential but not complex I NADH dehydrogenase activity, thus reducing cellular ATP biosynthesis and migration of macrophages. Ann N Y Acad Sci 2005, 1042:168-176.
27. Chen R.M., Wu C.H., Chang H.C., Wu G.J., Lin Y.L., Sheu J.R. Propofol suppresses macrophage functions and modulates mitochondrial membrane potential and cellular adenosine triphosphate synthesis. Anesthesiology 2003, 98(5):1178-1185.
28. Sietses C., Wiezer M.J., Eijsbouts Q.A., Beelen R.H., van Leeuwen P.A., von Blomberg B.M. A prospective randomized study of the systemic immune response after laparoscopic and conventional Nissen fundoplication. Surgery 1999, 126(1):5-9.
29. Brune I.B., Wilke W., Hensler T., Feussner H., Holzmann B., Siewert J.R. Normal T lymphocyte and monocyte function after minimally invasive surgery. Surg Endosc 1998, 12(8):1020-1024.
30. Kloosterman T., von Blomberg B.M., Borgstein P., Cuesta M.A., Scheper R.J., Meijer S. Unimpaired immune functions after laparoscopic cholecystectomy. Surgery 1994, 115(4):424-428.
31. Novitsky Y.W., Czerniach D.R., Kaban G.K., Bergner A., Gallagher K.A., Perugini R.A., et al. Immunologic effects of hand-assisted surgery on peritoneal macrophages: comparison to open and standard laparoscopic approaches. Surgery 2006, 139(1):39-45.
32. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332(20):1351-1362.
33. Kennedy B.C., Hall G.M. Neuroendocrine and inflammatory aspects of surgery: do they affect outcome?. Acta Anaesthesiol Belg 1999, 50(4):205-209.
34. Larsson E.L. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 1980, 124(6):2828-2833.
35. Arya S.K., Wong-Staal F., Gallo R.C. Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA. J Immunol 1984, 133(1):273-276.
36. Palacios R., Sugawara I. Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol 1982, 15(1):25-31.
37. Nieto M.A., González A., Gambón F., Díaz-Espada F., López-Rivas A. Apoptosis in human thymocytes after treatment with glucocorticoids. Clin Exp Immunol 1992, 88(2):341-344.
38. Dhabhar F.S., Miller A.H., McEwen B.S., Spencer R.L. Stress-induced changes in blood leukocyte distribution. Role of adrenal steroid hormones. J Immunol 1996, 157(4):1638-1644.
39. Flower R.J. Eleventh Gaddum memorial lecture. Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol 1988, 94(4):987-1015.
40. Sallenave J.M., Shulmann J., Crossley J., Jordana M., Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994, 11(6):733-741.
41. Mulligan M.S., Lentsch A.B., Huber-Lang M., Guo R.F., Sarma V., Wright C.D. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol 2000, 156(3):1033-1039.
42. Umland S.P., Schleimer R.P., Johnston S.L. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002, 15(1):35-50.
43. Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J.G., et al. The type II " receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994, 179(2):739-743.
44. Mozo L., Gayo A., Suárez A., Rivas D., Zamorano J., Gutiérrez C. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different posttranscriptional mechanisms. J Allergy Clin Immunol 1998, 102(6 Pt 1):968-976.
45. Kusnecov A.W., Rossi-George A. Potentiation of interleukin-1beta adjuvant effects on the humoral immune response to antigen in adrenalectomized mice. Neuroimmunomodulation 2001, 9(2):109-118.
46. Venihaki M., Dikkes P., Carrigan A., Karalis K.P. Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 2001, 108(8):1159-1166.
47. Sapolsky R., Rivier C., Yamamoto G., Plotsky P., Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987, 238(4826):522-524.
48. Panuncio A.L., De La Peña S., Gualco G., Reissenweber N. Adrenergic innervation in reactive human lymph nodes. J Anat 1999, 194(Pt 1):143-146.
49. de Coupade C., Gear R.W., Dazin P.F., Sroussi H.Y., Green P.G., Levine J.D. Beta 2-adrenergic receptor regulation of human neutrophil function is sexually dimorphic. Br J Pharmacol 2004, 143(8):1033-1041.
50. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000, 52(4):595-638.
51. Chen D., Rothenberg E.V. Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J Exp Med 1994, 179(3):931-942.
52. Tamir A., Isakov N. Cyclic AMP inhibits phosphatidylinositol-coupled and -uncoupled mitogenic signals in T lymphocytes. Evidence that cAMP alters PKC-induced transcription regulation of members of the jun and fos family of genes. J Immunol 1994, 152(7):3391-3399.
53. Gan X., Zhang L., Solomon G.F., Bonavida B. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Brain Behav Immun 2002, 16(3):227-246.
54. Hellstrand K., Hermodsson S. An immunopharmacological analysis of adrenaline-induced suppression of human natural killer cell cytotoxicity. Int Arch Allergy Appl Immunol 1989, 89(4):334-341.
55. Mirza Z.N., Kato M., Kimura H., Tachibana A., Fujiu T., Suzuki M., et al. Fenoterol inhibits superoxide anion generation by human polymorphonuclear leukocytes via beta-adrenoceptor-dependent and -independent mechanisms. Ann Allergy Asthma Immunol 2002, 88(5):494-500.
56. Bloemen P.G., van den Tweel M.C., Henricks P.A., Engels F., Kester M.H., van de Loo P.G., et al. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997, 272(4 Pt 1):L580-L587.
57. Kitamura T., Ohno N., Bougaki M., Ogawa M., Yamada Y. Masui 2008, 57(8):968-972.
58. Le Cras A.E., Galley H.F., Webster N.R. Spinal but not general anesthesia increases the ratio of T helper 1 to T helper 2 cell subsets in patients undergoing transurethral resection of the prostate. Anesth Analg 1998, 87(6):1421-1425.
59. Beilin B., Shavit Y., Cohn S., Kedar E. Narcotic-induced suppression of natural killer cell activity in ventilated and nonventilated rats. Clin Immunol Immunopathol 1992, 64(2):173-176.
60. Fuchs B.A., Pruett S.B. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. J Pharmacol Exp Ther 1993, 266(1):417-423.
61. Eisenstein T.K., Hilburger M.E. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 1998, 83(1-2):36-44.
62. Freier D.O., Fuchs B.A. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J Pharmacol Exp Ther 1994, 270(3):1127-1133.
63. Flores L.R., Dretchen K.L., Bayer B.M. Potential role of the autonomic nervous system in the immunosuppressive effects of acute morphine administration. Eur J Pharmacol 1996, 318(2-3):437-446.
64. Carr D.J., DeCosta B.R., Kim C.H., Jacobson A.E., Guarcello V., Rice K.C., et al. Opioid receptors on cells of the immune system: evidence for delta- and kappa-classes. J Endocrinol 1989, 122(1):161-168.
65. Graham E.A. The influence of ether and ether anaesthesia on bacteriolysis, agglutination, and phagocytosis. J Infect Dis 1911, 8:147-175.
66. Ricci C., Pastukh V., Mozaffari M., Schaffer S.W. Insulin withdrawal induces apoptosis via a free radical-mediated mechanism. Can J Physiol Pharmacol 2007, 85(3-4):455-464.
67. Tartter P.I., Steinberg B., Barron D.M., Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987, 122(11):1264-1268.
68. Levy S.M., Herberman R.B., Maluish A.M., Schlien B., Lippman M. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. Health Psychol 1985, 4(2):99-113.
69. Schantz S.P., Brown B.W., Lira E., Taylor D.L., Beddingfield N. Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 1987, 25(2):141-148.
70. Fujisawa T., Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung. Cancer 1997, 79(3):474-481.
71. Wakefield C.H., Carey P.D., Foulds S., Monson J.R., Guillou P.J. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993, 80(2):205-209.
72. Duignan J.P., Collins P.B., Johnson A.H., Bouchier-Hayes D. The association of impaired neutrophil chemotaxis with postoperative surgical sepsis. Br J Surg 1986, 73(3):238-240.
73. Ahlers O., Nachtigall I., Lenze J., Goldmann A., Schulte E., Höhne C., et al. Intraoperative thoracic epidural anaesthesia attenuates stress-induced immunosuppression in patients undergoing major abdominal surgery. Br J Anaesth 2008, 101(6):781-787.
74. Page G.G., Blakely W.P., Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001, 90(1-2):191-199.
75. Beilin B., Grinevich G., Yardeni I.Z., Bessler H. Tramadol does not impair the phagocytic capacity of human peripheral blood cells. Can J Anaesth 2005, 52(10):1035-1039.
76. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract.
77. Mahdy A.M., Galley H.F., Abdel-Wahed M.A., el-Korny K.F., Sheta S.A., Webster N.R. Differential modulation of interleukin-6 and interleukin-10 by diclofenac in patients undergoing major surgery. Br J Anaesth 2002, 88(6):797-802.
78. Kendall S.J., Weir J., Aspinall R., Henderson D., Rosson J. Erythrocyte transfusion causes immunosuppression after total hip replacement. Clin Orthop Relat Res 2000, (381):145-155.
79. Kehlet H., Nielsen H.J. Impact of laparoscopic surgery on stress responses, immunofunction, and risk of infectious complications. New Horiz 1998, 6(Suppl. 2):S80-S88.
80. Bessler M., Whelan R.L., Halverson A., Treat M.R., Nowygrod R. Is immune function better preserved after laparoscopic versus open colon resection?. Surg Endosc 1994, 8(8):881-883.
81. Stewart B.T., Stitz R.W., Lumley J.W. Laparoscopically assisted colorectal surgery in the elderly. Br J Surg 1999, 86(7):938-941.
82. Basse L., Madsen J.L., Billesbølle P., Bardram L., Kehlet H. Gastrointestinal transit after laparoscopic versus open colonic resection. Surg Endosc 2003, 17(12):1919-1922.
83. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178(4):1223-1230.
84. Smyth M.J., Taniguchi M., Street S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000, 165(5):2665-2670.
85. Zou J.P., Yamamoto N., Fujii T., Takenaka H., Kobayashi M., Herrmann S.H., et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995, 7(7):1135-1145.
86. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13(2):155-168.
87. Kobayashi T., Shiiba K., Satoh M., Hashimoto W., Mizoi T., Matsuno S., et al. Interleukin-12 administration is more effective for preventing metastasis than for inhibiting primary established tumors in a murine model of spontaneous hepatic metastasis. Surg Today 2002, 32(3):236-242.
88. Hurteau J.A., Blessing J.A., DeCesare S.L., Creasman W.T. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2001, 82(1):7-10.
89. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3(3):409-417.
90. Schwartz Y., Avraham R., Benish M., Rosenne E., Ben-Eliyahu S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res Treat 2008, 107(2):211-223.
91. Dithmar S., Rusciano D., Lynn M.J., Lawson D.H., Armstrong C.A., Grossniklaus H.E. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol 2000, 118(8):1085-1089.
92. Gallagher W.J., Dubinett S.M., Hoover H.C., Kradin R.L. Efficacy of adjuvant interleukin-2 after excision of BALB/c fibrosarcomas. Surgery 1989, 106(2):120-125.
93. Caprotti R., Brivio F., Fumagalli L., Nobili C., Degrate L., Lissoni P., et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res 2008, 28(3B):1951-1954.
94. Brivio F., Lissoni P., Alderi G., Barni S., Lavorato F., Fumagalli Nonalcoholic steatohepatitis. Oncology 1996, 53(4):263-268.
95. Brivio F., Lissoni P., Fumagalli L., Girlando M., Marsili M.T., Nespoli A., et al. Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer. Oncol Rep 1999, 6(6):1205-1207.
96. Hsueh E.C., Essner R., Foshag L.J., Ollila D.W., Gammon G., O'Day S.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002, 20(23):4549-4554.